SAFETY information for denosumab medicines (Prolia and biosimilars) used to treat osteoporosis has been updated, the Therapeutic Goods Administration (TGA) has advised.
The existing warning for multiple spinal fractures after discontinuation or delay of treatment injections has been strengthened.
New spinal fractures have occurred as early as seven months after the last dose of the drug, which is administered six-monthly.
The safety update stresses that people being treated with denosumab should not stop or delay treatment without speaking to their doctor, and prescribers should consider switching patients to an alternative therapy if treatment is discontinued.
Health professionals including pharmacists are urged to communicate with each other and with patients around the requirements of the treatment - more HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Nov 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Nov 25
